Luminary Therapeutics, Inc. Press Releases - EIN Presswire

Published on December 20, 2023 - 11:45 GMT

Luminary Therapeutics Announces FDA Clearance of Phase I, IND for a BAFF CAR to Treat Systemic Lupus Erythematosus (SLE)

Luminary Therapeutics Announces FDA Clearance of IND for LMY-920, a Novel BAFF CAR T-Cell Therapy to Treat Systemic Lupus Erythematosus (SLE). MINNEAPOLIS, MN, UNITED STATES, December 20, 2023 /⁨EINPresswire.com⁩/ -- Luminary Therapeutics ("Luminary …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on June 13, 2023 - 14:43 GMT

Luminary and UNC enter into a License Agreement for an Optimized Dual Targeting CAR designed for solid tumors

Luminary Tx and UNC enter into a formal License Agreement for clinical development of an Optimized CSPG4 Dual Targeting CAR designed to treat solid tumors! MINNEAPOLIS, MN, UNITED STATES, June 13, 2023 /⁨EINPresswire.com⁩/ -- Luminary Therapeutics and …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on December 7, 2022 - 11:45 GMT

Dr. Joseph Eid to join Luminary Therapeutics as Chief Medical Officer

Luminary announces a new Chief Medical Officer MINNEAPOLIS, MN, UNITED STATES, December 7, 2022 /⁨EINPresswire.com⁩/ -- Luminary is announcing the appointment of Dr. Joseph Eid as the organization's new fractional Chief Medical Officer (CMO). Dr. Eid …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on July 19, 2022 - 11:30 GMT

Luminary Therapeutics selected as a 2022/2023 Showcase Company in NIH/NCI’s investor initiative program

Luminary Therapeutics a clinical stage gamma delta allogeneic cellular therapy company. MINNEAPOLIS, MN, USA, July 19, 2022 /⁨EINPresswire.com⁩/ -- Luminary Therapeutics was selected as a 2022/2023 Showcase Company in NIH/NCI’s investor initiative program …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...